MAPIE Failed to Improve Responses in High-grade Osteosarcoma

Share this content:
Addition of ifosfamide and etoposide to adjuvant cisplatin, doxorubicin, and high-dose methotrexate did not improve event-free survival.
Addition of ifosfamide and etoposide to adjuvant cisplatin, doxorubicin, and high-dose methotrexate did not improve event-free survival.

Editor's Note: A previous version of this article incorrectly referred to the treatment arm of this study as MAP; MAPIE, not MAP, failed to improve responses in this setting.

The addition of ifosfamide and etoposide to adjuvant cisplatin, doxorubicin, and high-dose methotrexate (MAP) did not improve event-free survival of patients with newly diagnosed, high-grade osteosarcoma, who respond poorly to neoadjuvant chemotherapy, according to a study published in The Lancet Oncology.1

For this open-label, phase 3 EURAMOS-1 trial, investigators enrolled 618 patients aged 40 years or younger with newly diagnosed osteosarcoma, each of whom had a poor response to preoperative chemotherapy.

After resection, participants were randomly assigned 1:1 to receive MAP or MAP plus ifosfamide and etoposide (MAPIE).

With a median follow-up of 62.1 months, there was no significant difference in event-free survival between the 2 treatment arms (hazard ratio, 0.98; 95% CI, 0.78-1.23).

Patients treated with MAPIE experienced higher rates of grade non-hematologic toxicity than those in the MAP group, though rates of grade 3 to 4 neutropenia and thrombocytopenia were similar between the groups.

One patient in the MAP arm died due to treatment-related infection, and 1 patient died as a result of left ventricular systolic dysfunction in the MAPIE arm, likely due to study treatment.

RELATED: High Circulating CXCL10, FLT3LG Levels May Predict Worse Survival in Osteosarcoma

The findings suggest that adjuvant MAP chemotherapy should be the standard of care for these patients who have a poor response to preoperative chemotherapy, but new treatment strategies are needed to improve clinical outcomes in this setting.

Reference

  1. Marina NM, Smeland S, Bielack SS, et al. Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial. Lancet Oncol. 2016 Aug 25. doi: 10.1016/S1470-2045(16)30214-5 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters